Piper Jaffray Reiterates an Overweight on ABIOMED (ABMD); Raises PT
ABMD Hot Sheet
Rating Summary:4 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Piper Jaffray & Co. reiterates an Overweight on ABIOMED, Inc. (Nasdaq: ABMD); raises price target from $10 to $12
Piper analyst says, "Given the recent positive clinical news flow from TCT and increasing appetite by investors for small/mid cap growth stocks, we think there's additional upside in ABMD from current levels...Abiomed has been one of the top performing stocks in our coverage universe. The stock has nearly doubled since this past April. While we think much of the easy money stock has been made, we think there's further upside to the stock, and as such, we are maintaining our Overweight rating...Our price target is based on the stock trading at ~4.0x (prev. 3.5x) on an EV to calendar 2010 sales basis (sales $99.5M, net cash $55M, 37.4M shares)."
To see more analyst ratings on ABMD Click Here.
Abiomed, Inc. and its subsidiaries manufacture and sell medical devices in circulatory support that offer a continuum of care in heart recovery to acute heart failure patients.
Piper analyst says, "Given the recent positive clinical news flow from TCT and increasing appetite by investors for small/mid cap growth stocks, we think there's additional upside in ABMD from current levels...Abiomed has been one of the top performing stocks in our coverage universe. The stock has nearly doubled since this past April. While we think much of the easy money stock has been made, we think there's further upside to the stock, and as such, we are maintaining our Overweight rating...Our price target is based on the stock trading at ~4.0x (prev. 3.5x) on an EV to calendar 2010 sales basis (sales $99.5M, net cash $55M, 37.4M shares)."
To see more analyst ratings on ABMD Click Here.
Abiomed, Inc. and its subsidiaries manufacture and sell medical devices in circulatory support that offer a continuum of care in heart recovery to acute heart failure patients.
You May Also Be Interested In
- Barclays Cuts Estimates and Price Target on ADP (ADP); Mixed Data From Investor Day
- Barclays on U.S. Specialty Pharmaceuticals: Model Updates on FRX, MRX, WCRX & PCRX
- Needham & Company Reiterates a 'Buy' on UQM Technologies (UQM); Increasing EV Adoption
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Piper JaffraySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
